OBJECTIVE—The activation of β-cell genes, particularly of those encoding preproinsulin, requires an appropriate euchromatin (or “open”) DNA template characterized by hypermethylation of Lys4 of histone H3. We hypothesized that this modification is maintained in islet β-cells by the action of the histone methyltransferase Set7/9.

RESEARCH DESIGN AND METHODS—To identify the role of Set7/9, we characterized its expression pattern and gene regulation and studied its function using RNA interference in both cell lines and primary mouse islets.

RESULTS—Within the pancreas, Set7/9 protein shows striking specificity for islet cells, including α- and β-cells, as well as occasional cells within ducts. Consistent with these findings, the Set7/9 gene promoter contained an islet-specific enhancer located between −5,768 and −6,030 base pairs (relative to the transcriptional start site) that exhibited Pdx1-responsive activation in β-cells. To study Set7/9 function, we depleted insulinoma cells and primary mouse islets of Set7/9 protein using siRNA. Following siRNA treatment, we observed striking repression of those encoding preproinsulin, requiring an appropriate euchromatin structure at genes necessary for glucose-stimulated insulin secretion, including Ins1/2, Glut2, and Mafa. These changes in transcription were accompanied by loss of dimethylated H3 Lys4 and RNA polymerase II recruitment, particularly at the Ins1/2 and Glut2 genes. Consistent with these data, depletion of Set7/9 in islets led to defects in glucose-stimulated Ca2+ mobilization and insulin secretion.

CONCLUSIONS—we conclude that Set7/9 is required for normal β-cell function, likely through the maintenance of euchromatin structure at genes necessary for glucose-stimulated insulin secretion. Diabetes 58:185–193, 2009

Methyltransferase Set7/9 Maintains Transcription and Euchromatin Structure at Islet-Enriched Genes

Tye G. Deering, Takeshi Ogihara, Anthony P. Trace, Bernhard Maier, and Raghavendra G. Mirmira

β-cell gene transcription will be paramount in these efforts. In recent years, a model has been emerging that emphasizes the role of β-cell–specific transcription factors such as Pdx1, Nkx6.1, NeuroD1, and Maf factors in the expression and regulation of genes crucial to the development and function of β-cells (recent reviews in 2–4). However, transcription of a variety of non–β-cell types with these and other transcription factors has yielded limited success in activating β-cell genes and suggests that this model of β-cell gene activation requires further refinement. In this regard, chromatin structure is becoming recognized as a crucial factor in modulating eukaryotic gene expression. Covalent modifications of the histone proteins H2A, H2B, H3, and H4 that make up the fundamental unit of chromatin have been shown to directly or indirectly lead to the formation of euchromatin (“open,” or active, chromatin) or heterochromatin (“closed,” or inactive, chromatin) (5–7). These modifications include methylation, acetylation, phosphorylation, and ubiquitination of specific amino acid residues in the N-terminal histone tails. The roles of chromatin and histone modifications in β-cell gene transcription have received attention only in recent years.

Our laboratory and others have been particularly interested in the role of methylation of Lys4 of H3 in the activation of β-cell genes. For example, recent studies have demonstrated that H3-Lys4 methylation at the control region of the genes encoding cell cycle inhibitors p27Kip1 and p18Ink4c is crucial in their activation and subsequent suppression of β-cell tumorigenesis (8). Maintenance of this methylation state appears to involve a complex containing the protein menin and members of the SET methyltransferase family, the mixed lineage leukemia proteins (9). Similarly, our laboratory has demonstrated that mono- and dimethylation of H3 Lys4 is enriched in the control region of the gene encoding preproinsulin (Ins1/2) and that the maintenance of dimethylated H3 Lys by a transcriptional protein complex involving Pdx1 is crucial to the ongoing activation of this gene in β-cell lines (10,11). Because Pdx1 contains no methyltransferase activity, we proposed that another member of the SET protein family, Set7/9, may be recruited to a complex with Pdx1 to mediate H3 methylation at the Ins1/2 gene (10). Set7/9 is a 366 amino acid enzyme containing a COOH-terminal SET domain that harbors methyltransferase activity (12,13). This methyltransferase activity is specific not only for H3 Lys4 but also for particular Lys residues in proteins such as p53, TAF10, and the estrogen receptor (14–19). However, consistent with a direct role in gene transcription in the islet, our prior studies using chromatin-reconstituted reporters in vitro showed that the interaction of Pdx1 with Set7/9 leads to synergistic gene activation in a methyltransferase-dependent manner (11). These data have led us to hypothesize that Set7/9 may represent a novel chromatin-modifying protein that functions in part...
through its recruitment to target genes by cell-specific transcription factors such as Pdx1. In this study, we show that Set7/9 is strongly enriched in islets relative to other pancreatic cell types and that it is important in the maintenance of transcription and chromatin structure at genes necessary for glucose-stimulated insulin secretion in primary islets. Taken together, our data identify Set7/9 as a novel enzymatic cofactor necessary for maintenance of islet gene transcription.

**RESEARCH DESIGN AND METHODS**

**Antibodies and cells.** Polyclonal antibody against monomethyl–H3 Lys4 was from Abcam, and antibodies against dimethylated H3 Lys4, Pdx1, and Set7/9 were from Millipore; anti-RNA polymerase II COOH-terminal domain was from Covance; anti-actin, anti-glucagon, and anti-insulin were from Santa Cruz Biotechnology. βTC3 cells, INS-1 (S32/13), αTC1.6, and NHE3T7 were maintained as previously described (20,21). Islets were isolated from C57BL/6J mice following collagenase digestion of pancreatic tissue as previously described (22). Techniques and protocols were approved by the Indiana University Institutional Animal Care and Use Committee.

**Real-time RT-PCR.** Real time RT-PCR was performed with forward and reverse primers to amplify insulin premRNA (5′-GGGGAGCGTGGCTTCT-3′ and 5′-GGGGACAGAATTCAGTGGCA-3′) or Actb (5′-AGGUAGCAGUUG-3′ and 5′-CGGACAGAUUU-GACCAUUU-3′) as previously described in detail (23). Primers for Setd7, Set2a2, Gck, Nks6-1, NeuroD1, Pdx1, Pax6, Iapp, Mafa, Ipf1, Kunj11, Abe8, and Foxa2 were obtained from Qagen (Quantitech primer kit catalog nos. QT0019727, QT0010357, QT00140007, QT0014318, QT00251265, QT0016186, QT00125786, QT00101552, QT01035768, QT00102235, QT00305319, and QT00242900, respectively). PCR products were subcloned and sequenced to verify amplification of the correct gene product. All values are normalized to Actb mRNA levels.

**Immunoblot.** Whole-cell extracts were prepared from homogenized tissues, 50 islets, or 1 × 106 βTC3 cells by lysis in a buffer containing sodium dodecyl sulfate, and 5 μg extract was resolved by electrophoresis on a 12% SDS-polyacrylamide gel followed by immunoblot with anti-Set7/9 or anti-actin antiserum. Immunoblots were visualized using the ECL-Plus system (Amersham). Chromatin immunoprecipitation assays. Chromatin immunoprecipitation (ChIP) assays were performed as previously described (20). Briefly, 106 βTC3 cells or 300 mouse islets were fixed in 1% formaldehyde to cross-link proteins to DNA, and cells were lysed and chromatin sheared to 400–600 base pairs (bp) by sonication. Antibodies were used to subsequently immunoprecipitate the protein of interest and then recovery of coimmunoprecipitated DNA fragments was assessed using real-time RT-PCR. Data are expressed as the percent recovery of coimmunoprecipitated DNA relative to input DNA (before immunoprecipitation). Primers used for amplification were as follows: for the Ins1/2 promoter, 5′-TACCTGTCCTGAGTTCTCTG-3′ and 5′-GCATTTTCACATCATCTTCC-3′ reverse; the Ins1/2 coding region, 5′-TGGCTCTTUCACACCACAG-3′ forward and 5′-ACAATGGCAACCTCTTGCG-3′ reverse; the Set7 promoter, 5′-ATCTGTCCTCGCACCCTCCTCTC-3′ forward and 5′-CCCTGTCATTTCTGTTAGG-3′ reverse; the Pdx1 promoter, 5′-AGCCTGGAACACTCTGAGTTC-3′ forward and 5′-TACCTAAAACCCGCTCTCAATGAG-3′ reverse; and the Setd7 promoter, 5′-TCTTGTTGCCCATCATCAAA-3′ forward and 5′-ACATGAAACGCCACATGAA-3′ reverse.

**Immunohistochemistry.** Mouse pancreata were fixed by cardiac perfusion with 4% paraformaldehyde, paraffin embedded, and sectioned at 5-μm intervals. Human pancreatic samples were obtained from the University of Virginia Human Islet Transplant Program, fixed for 2 h in 4% paraformaldehyde, and processed similarly to mouse pancreata. Immunohistochemical analysis of insulin (anti-insulin, 1:500 dilution), Pdx1 (anti-Pdx1, 1:2,000 dilution), glucagon (anti-glucagon, 1:500 dilution), and Set7/9 (anti-Set7/9, 1:50), was performed as previously described (11). For immunofluorescence, secondary antibodies were goat anti-rabbit–conjugated to Alexa Fluor 555 and donkey anti-mouse–conjugated to Alexa Fluor 488 (Molecular Probes). Images were acquired using a Zeiss Z1 microscope equipped with Apotome optical sectioning hardware.

**Transfection of cell lines with siRNA.** siRNAs against Set7/9 or a scrambled control were mixed with Reagent V (Ambion, Inc.) and transfection into 3 × 106 βTC3 mouse islet cells or into human leukemia cells using an Amban Xenocelector (program 23) according to the manufacturer’s protocol. Cells were then plated in a six-well culture medium for 24 h and then harvested for protein, total RNA, or ChIP analysis. siRNA sequences used were as follows: siSet7, 5′-GGUUUAGUUUGGCGACUTTT-3′; siSet8, 5′-GGUAGCAGUGG-GACUAATT-3′; and a control siRNA (siControl), 5′-AAAGUGCGACCUG-CAGAUGUUU-3′.

**In vivo delivery of siRNA.** Stabilized siRNAs were obtained from Dharmacon and diluted in 0.9% saline. Eight-week-old male C57BL/6J mice were injected intraperitoneally with 1.6 mg/kg mouse wt siRNA daily for 4 days. Islets were then harvested, handpicked and allowed to recover overnight and then subjected to glucose-stimulated insulin secretion (GSIS)/glucose-stimulated Ca2+ mobilization (GSCa) studies (see below), protein isolation, or RNA isolation. siRNA sequences used were as follows: siSet1, 5′-CAGGACAGAUAUGGGCAGAUU-3′; siSet2, 5′-GGGUUAUGUUGCCGACUU-3′; and siControl, 5′-AAAGUGCGACCUGCAGAUGUU-3′.

**GSIs and GSCa studies.** For GSIs studies, 50 islets per condition were incubated in Krebs-Ringer HEPES buffered solution for 1 h at 37°C and then placed in Krebs-Ringer HEPES buffered solution containing 3 or 11 mmol/l glucose for 1 h. Insulin released into the medium was assayed using a two-site immunoassay ELISA (Alpco Diagnostics). GSCa in mouse islets was measured using the ratiometric Ca2+ indicator Fura-2AM as described previously.
GSCa was defined as the difference between ratio measurements (340/380 nm fluorescence) in 11 mmol/l vs. 3 mmol/l glucose. Data were analyzed with IP Lab software, version 4.0 (Scanalytics).

Cloning of the Setd7 promoter. A genomic clone containing 8,000 bp of the Setd7 gene was used as a template in PCR reactions to generate various fragments of the Setd7 gene, which were then subcloned upstream of the luciferase coding sequence in plasmid pFoxLuc (25). Mutagenesis of the Setd7 gene was performed using the QuickChange Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions. All sequences were confirmed by automated DNA sequencing.

Transfections and reporter assays. $10^6 \beta $TC3/α TC1.6/INS-1 cells or $5 \times 10^5$ NIH3T3 cells were seeded in six-well plates 24 h before transfection. Plasmid (2 μg) diluted into 0.1 ml PBS was mixed with 6 μl of Metafectene Pro (Biotex) and incubated at room temperature for 15 min. The transfection mixture was added to each well of a six-well plate along with 2 ml medium without antibiotics. At 6 h after transfection, the medium was replaced with

FIG. 2. Regulation of the mouse Setd7 gene. A: Fragments of the Setd7 promoter in plasmid pFoxLuc1 (pFLO) were transfected into the cell lines indicated. Luciferase activity was measured 48 h after transfection, corrected for total protein, and normalized to the activity of the promoterless backbone plasmid. B: An A/T-rich DNA fragment of the Setd7 promoter (−5,768 to −6,030) was subcloned into a luciferase reporter plasmid driven by the prolactin minimal promoter (pFLprl) and transfected into the cell lines indicated. Luciferase activity was normalized to the activity of pFLprl-transfected cells. C and D: Setd7 gene fragments (wild-type and mutagenized at potential Pdx1 binding sites) were cotransfected with a cytomegalovirus promoter-driven plasmid (pBAT12) expressing Pdx1 into either βTC3 (C) or INS-1 (D) cells. Luciferase activity was normalized to the activity of cells transfected with the backbone pBAT12 plasmid. Data in all panels represent the average of at least three independent transfections. E: Results of a ChIP assay using βTC3 cell chromatin and either normal rabbit serum (−Ab) or primary antibody to Pdx1 (Pdx1 Ab). Recovery of either the Setd7 or Actb promoters were quantitated by real-time PCR, and data are expressed as fold recovery compared with the data for normal rabbit serum alone. The amplified region of the Setd7 gene (in bp) relative to the transcriptional start site is indicated in parentheses. Data represent the average from three independent ChIP experiments.
fresh medium containing antibiotics. At 48 h after transfection, cells were harvested and a luciferase assay was performed utilizing a commercially available luminometric kit (Promega). Luciferase activity was normalized to protein concentration as measured using the Bio-Rad Protein Assay reagent (Bio-Rad) according to manufacturer’s instructions.

RESULTS

Set7/9 mRNA and protein are enriched in pancreatic islets. To evaluate the tissue distribution of Set7/9 in adult mice, Set7/9 mRNA and protein were assayed in different tissues by real-time RT-PCR and immunoblot, respectively. As shown in Fig. 1A, mRNA levels demonstrate a pattern of tissue-specific enhancement, with the highest relative levels seen in muscle, brain, heart, and pancreas. Interestingly, Set7/9 protein levels do not completely mirror Set7/9 mRNA levels (Fig. 1B), as no protein was detectable in either heart or total pancreas and very little was detectable in muscle. These data suggest the potential for posttranscriptional regulation of Set7/9 expression. However, within the pancreas, there was clear enrichment of Set7/9 protein within islets as determined by immunoblotting (Fig. 1B). To directly visualize the distribution of Set7/9 among pancreatic cell types, we next performed immunohistochemistry of pancreatic sections from both mice and humans. Figure 1C and D shows that Set7/9 is strikingly enriched in islets of mouse pancreas, with a predominantly nuclear pattern in most cells of the central islet.

Coimmunofluorescence revealed that Set7/9 exhibited a nuclear pattern in insulin-producing β-cells (Fig. 1E–G) and both a nuclear and cytoplasmic pattern in glucagon-producing α-cells (Fig. 1H–J). All Pdx1-positive cells of the islet costained for Set7/9 (Fig. 1K–M). Human pancreas sections demonstrated a Set7/9 staining pattern identical to that seen in mouse sections (supplemental Fig. S1, available in an online appendix at http://dx.doi.org/10.2337/db08-1150).

β-Cell–specific transcription of the Setd7 gene. The islet-specific enrichment of Set7/9 suggested the potential for regulation at the transcriptional level. To explore this possibility, we placed a range of DNA fragments from the 5′ regulatory region of the gene encoding Set7/9 (Setd7) upstream of the luciferase reporter gene (in plasmid pFoxLuc [25]). These constructs were then transfected into the β-cell–derived cell lines βTC3 and INS-1, the α-cell–derived cell line αTC1.6, and the fibroblast-derived line NIH3T3. As shown in Fig. 2A, β-cell lines displayed enhancement of luciferase activity with a DNA fragment containing −6,584 bp upstream of the transcriptional start site. This enhancement was significantly attenuated when a fragment containing −3,131 bp from the transcriptional start site was used, suggesting the potential for a β-cell–specific enhancer located between −3,131 and −6,584 bp.

To further explore this possibility, we next performed an
alignment of human, mouse, and rat Setd7 genes to identify regions of homology that might suggest conserved β-cell–specific enhancer regions. Although the entire region between 3,131 and 6,584 bp only exhibited 25% identity between these species (data not shown), we identified a region between 5,768 and 6,030 bp that exhibited 68% identity (supplemental Fig. S2). Within this conserved region, we identified two potential binding sites for the β-cell–specific transcription factor Pdx1 (consensus: 5'-TAAT-3' [refs. 20,26]) (supplemental Fig. S2). To directly test whether this region of the Setd7 gene might be regulated in β-cells, a DNA fragment containing this conserved region was placed upstream of the prolactin minimal promoter driving luciferase and used in reporter gene analysis studies. As shown in Fig. 2B, this fragment displayed relative enhancement of luciferase activity in βTC3 and INS-1 β-cell lines, but not in NIH3T3 cells. Upon cotransfection with a plasmid encoding Pdx1, this fragment displayed an ~25-fold enhancement in the β-cell lines INS-1 and βTC3 (Fig. 2C and D). Mutation of either putative Pdx1 binding site attenuated activity of this fragment in both β-cell lines (Fig. 2C and D). Pdx1 appears to occupy the endogenous Setd7 gene in βTC3 cells within


**FIG. 6.** Set7/9 is necessary for the maintenance of dimethylated H3 Lys4 at specific genes in βTC3 cells. βTC3 cells were transfected with the siRNAs indicated and subjected to ChIP using either normal rabbit serum (−Ab) or antibodies to methylated histones. Recovery of the gene fragments was assessed by real-time PCR. Data are reported as recovery of the indicated gene (Ins1/2 or Slc2a2) following ChIP as a percent of the input levels of the gene before ChIP. A: Percent recovery of dimethylated H3 Lys4 at the Ins1/2 promoter and coding regions. B: Percent recovery of dimethylated H3 Lys4 at the Slc2a2 promoter and coding regions. C: Percent recovery of dimethylated H3 Lys4 at the Pdx1 proximal promoter region. D: Percent recovery of dimethylated H3 Lys4 at the Pdx1 proximal promoter region. Data represent the average of at least three independent ChIP assays from at least three independent siRNA transfections. *Statistically different (P < 0.05) from data of siControl transfections. The amplified region of the genes (in bp) relative to the transcriptional start site is indicated in parentheses below each gene. ■, siControl; □, siSet97; □, siSet98.

the region around −6,000 bp, as assessed by the ChIP assay, but does not occupy the endogenous gene encoding β-actin (Fig. 2E). Together, these results suggest that the Setd7 gene may contain elements that enhance its expression specifically in β-cells and that the islet transcription factor Pdx1 may be a necessary component of a transactivation complex on the Setd7 gene.

**Set7/9 is necessary for the expression of a subset of glucose-responsive genes in β-cell lines and islets.** To determine the role of Set7/9 in the regulation of β-cell-specific genes, we next depleted βTC3 cells of Set7/9 protein and analyzed gene expression by real-time RT-PCR. To knock down protein, two different siRNAs (siSet97 and siSet98) targeted against murine Set7/9 or siControl were then transfected into βTC3 cells. As shown in Fig. 3A, >90% reductions in Set7/9 protein were seen following transfections with each siRNA compared with those seen in control transfections. Use of two different siRNAs ensured that any effects on gene transcription were unlikely a result of off-target effects of these siRNAs. A survey of islet-specific genes involved in glucose responsiveness showed that the genes encoding the β-cell-specific transcription factor MafA (MafA), the glucose transporter Glut2 (Slc2a2), and preproinsulin (Ins1/2) were reduced significantly (Fig. 3B) in cells depleted of Set7/9. However, reduction was not seen uniformly among all genes responsible for glucose responsiveness in islets, as those encoding Pdx1 (Pdx1), the ATP-sensitive K⁺ channel (Kcnj11), sulfonylurea receptors (Abcc8), Nkx6.1 (Nkx6.1), and NeuroD1 (NeuroD1) appeared statistically unaffected by acute reductions in Set7/9 (Fig. 3B).

To confirm our findings in primary cells, we next performed knockdown experiments in mouse islets. However, a major challenge in RNA interference studies in primary rodent islets is their relatively poor transfection efficiency in vitro, which typically necessitates use of viral-based approaches (27). Instead, we sought to knock down Set7/9 in islets by delivering chemically stabilized siRNAs in vivo. A similar technique has been used to target other proteins for systemic knockdown (28,29). To test the efficacy of this approach in islets, we performed four daily intraperitoneal injections of Cy3-labeled double-stranded RNA into male C57BL/6J mice and subsequently isolated islets from these animals on day 5. As shown in Fig. 4A, fluorescent microscopic images of isolated islets revealed penetration of the Cy3 label into the islets, suggesting islet entry of siRNA. Two different stabilized siRNAs targeted against Set7/9 (siSet1 and siSet2) or siControl were then delivered to mice using the same approach. Following the injections, islets from mice were then harvested and
studied by immunoblot, real-time RT-PCR, GSCa, and GSIS. As shown in Fig. 4B, islet Set7/9 protein was reduced by at least 60% by treatment with either siRNA compared with control. Interestingly, similar knockdown was not observed in liver, brain, or muscle, suggesting that for the specific protocol employed, targeting of islets appeared to be most efficient.

Consistent with the data observed in βTC3 cells, depletion of Set7/9 in primary islets resulted in decreases in MafA, Slc2a2, and Ins1/2 (Fig. 5A). Because decreases in these genes would be predicted to result in loss of glucose responsiveness in islets, we tested islet functionality by these genes would be predicted to result in loss of glucose responsiveness in islets, we tested islet functionality by these genes. The GSCa assay is a Fura-2AM dye–based assay that measures the intracellular mobilization of Ca2+ in response to glucose and is dependent on an intact signaling cascade that begins with the transport of glucose into the β-cell by GLUT2 and ending in the activation of voltage-gated Ca2+ channels; intracellular Ca2+ mobilization through this cascade is closely linked to insulin secretion (30). As shown in Fig. 5B, reductions in islet Set7/9 protein using either siSet1 or siSet2 resulted in GSCa responses (from 3 to 11 mmol/l glucose) that were only ~50% those associated with control. These islets also showed diminished GSIS upon raising glucose from 3 to 11 mmol/l (Fig. 5C). Taken together, these results suggest that Set7/9 is necessary for the transcription of a subset of islet genes that are required for the maintenance of normal islet function.

Set7/9 is necessary for the maintenance of H3-Lys4 dimethylation at the Ins1/2 and S1c2a2 genes. In prior ChIP studies, we demonstrated that Set7/9 occupies the Ins1/2 genes in βTC3 cells (10). This observation, coupled with the finding that the Ins1/2 gene is hypermethylated at H3 Lys4 (10,11), suggested to us that Set7/9 may be directly responsible for the maintenance of this euchromatin histone modification at this gene. We therefore wondered whether the reduction in Ins1/2 gene activity observed upon knockdown of Set7/9 in this study could be secondary to loss of H3-Lys4 methylation. As shown in Fig. 6A, depletion of Set7/9 in βTC3 cells using either of two siRNAs (siSet97 or siSet98) led to 50–80% reductions in dimethylated H3 Lys4 in the Ins1/2 promoter region as determined by ChIP assay but did not affect dimethylated H3 Lys4 in the coding region of the gene. Importantly, we did not observe any changes to monomethylated H3 Lys4 in either the promoter or coding regions of the Ins1/2 gene (Fig. 6B), suggesting that Set7/9 is associated with a very specific dimethylation effect.

To ascertain the specificity of Set7/9, we next examined the genes S1c2a2 (whose transcription is reduced by loss of Set7/9) and Pdx1 (whose transcription is unaffected by loss of Set7/9). As shown in Fig. 6C and D, we observed a specific loss of dimethylated H3 Lys4 at the proximal S1c2a2 promoter but not at the proximal Pdx1 promoter. Similar results were obtained in primary mouse islets depleted of Set7/9 using siSet1, although the decreases in dimethylated H3 Lys4 at the Ins1/2 and S1c2a2 genes did not quite approach statistical significance (Fig. 7A). These results are consistent with gene-specific effects of Set7/9.

To determine whether Set7/9 could be modifying histones directly at the S1c2a2 gene, we next performed ChIP assays in βTC3 cells to assess recruitment of Set7/9 to this gene. Figure 7B shows that Set7/9 occupies the S1c2a2 gene within its proximal control region (−738 to −523 bp relative to the transcriptional start site) but was not detected at the proximal Pdx1 promoter. These results suggest that the chromatin effects observed at the S1c2a2 gene are the result of Set7/9 recruitment to its promoter. Set7/9 is necessary for the recruitment of RNA polymerase II to the Ins1/2 gene. Pdx1, like Set7/9, is required for the full activation of the Ins1/2 gene (23,31,32). This effect of Pdx1 is apparently related not to RNA polymerase II transcription by Set7/9 might be related to Pdx1. As shown in Fig. 8A, knockdown of Set7/9 in βTC3 cells using siSet97 led to no changes in Pdx1 occupancy at the Ins1/2 gene. However, we observed that RNA polymerase II recruitment to the promoter region of Ins1/2 (and S1c2a2) was diminished by ~50% (Fig. 8B). These results suggest that Set7/9 action at the Ins1/2 gene may be distinct from that of Pdx1 and that either Set7/9 itself or its associated dimethylated H3-Lys4 modification is linked to RNA polymerase II recruitment.

![Fig. 7. Set7/9 may be necessary for maintenance of dimethylated H3 Lys4 at the Ins1/2 and S1c2a2 genes in mouse islets and occupies the S1c2a2 gene in βTC3 cells. A: Male C57BL/6 mice were injected intraperitoneally with stabilized control siRNA or siRNA against Set7/9 (siSet1) as described in RESEARCH DESIGN AND METHODS. Islets were subsequently harvested and subjected to ChIP using either normal rabbit serum (−Ab) or antibody to dimethylated H3 Lys4 (+Ab). Data are reported as percent recovery of the indicated gene promoter relative to input. Data represent the average of three independent ChIP experiments from mice injected on three separate occasions. B: βTC3 cells were subjected to ChIP analysis using normal rabbit serum (−Ab) or antibody against Set7/9 (Set7/9 Ab). Recovery of the proximal S1c2a2 and Pdx1 promoters are reported as fold recovery relative to normal rabbit serum. Data represent the average of three independent ChIP assays. *Statistically different (P < 0.05) from data of ChIP assays in which normal rabbit serum was used in place of Set7/9 antibody.](image-url)
METHYLTRANSFERASE SET7/9 AND β-CELL FUNCTION

DISCUSSION

The islet β-cell derives many of its characteristics, particularly stimulus-secretion coupling, from the transcription of a unique subset of genes that is controlled by a group of cell-specific transcription factors and cofactors. In this report, we identify a new member of this cohort of islet-specific factors, Set7/9, and demonstrate its role in the maintenance of gene transcription and chromatin structure in β-cell lines and primary islets. Set7/9 was originally identified as a histone H3-Lys4–specific methyltransferase (12,13). Subsequently, Set7/9 was shown to methylate Lys residues in a variety of proteins including TAF10 (18), TAF7 (17), p53 (14–16), the estrogen receptor (19), and possibly Pdx1 (11). To date, however, its role in the maintenance of histone H3–Lys4 methylation at islet genes has only been implied (11) and not directly studied.

We show that Set7/9 is distributed in a limited number of tissues in the mouse but includes those derived from all three major germ layers, including ectoderm (brain), mesoderm (muscle), and endoderm (pancreas). Within the pancreas of both the mouse and human, Set7/9 exhibits a striking islet-specific distribution pattern. The enrichment of Set7/9 in β-cells may occur at the level of transcription, as our studies identified a potential conserved β-cell–specific enhancer located in the distal Setd7 gene that is responsive to Pdx1. Its strongly nuclear pattern of distribution, particularly in β-cells, suggested to us a role for Set7/9 in β-cell gene regulation.

To identify genes regulated by Set7/9 in β-cells, we engaged RNA interference approaches to knock down Set7/9 in insulinoma-derived β-cells (βTC3) and primary mouse islets. Successful knockdown using multiple different siRNAs demonstrated reductions in key genes that mediate stimulus-secretion coupling, including Slc2a2, Mafa, and Ins1/2. Consistent with these reductions, we observed impaired GSCa and GSIS in islets depleted of Set7/9. We note that our knockdown studies were of short duration by design in order to obtain information on the most immediate and potentially direct genetic targets of Set7/9. Thus, we cannot rule out the possibility that other genes may contribute to the dysfunctional islet phenotype observed or that more prolonged knockdown may not have broader effects on islet function, replication, or survival. Importantly, effects on islet survival are possible, given that recent studies suggest a role for Set7/9 in the maintenance of inflammatory genes in macrophages (33).

As noted earlier, Set7/9 exhibits specific methyltransferase activity toward histone H3 Lys4. Some studies suggest that it may function as a dimethyltransferase (34), whereas others suggest that it functions exclusively as a monomethyltransferase in vitro (35). Although our data are compatible with the role of Set7/9 as a dimethyltransferase in cells, they do not rule out the possibility that it may indeed function as a monomethyltransferase. For example, it is possible that Set7/9 is very closely linked to a second methyltransferase that completes the dimethylation reaction in cells, such that transient alterations in monomethylation are not detectable in our system. Alternatively, it is possible that catalytic activities observed in vitro are modified in the cellular milieu as a result of the complexity of protein-protein interactions. In this context, recent studies of the H3-Lys9 methyltransferase G9a show that it exhibits differing stoichiometries of methylation in vivo depending on binding to accessory proteins (36).

In the absence of endogenous nuclear localization and DNA binding domains, we presume that Set7/9 must be chaperoned to both the nucleus and target genes through an interaction with transcription factors. We have previously demonstrated that Set7/9 forms an immunoprecipitable complex with Pdx1 (11). In those studies, we also showed that depletion of Pdx1 in βTC3 cells leads to diminution of H3-Lys4 dimethylation at the Ins1/2 gene—an observation that our present studies suggest could be caused by disruption of the Pdx1-Set7/9 complex. Interestingly, however, whereas the depletion of Pdx1 led to defective conversion of RNA polymerase II to its elongation isoform (and not its recruitment to the promoter [11,23]), we observed here that depletion of Set7/9 causes impairments in RNA polymerase II recruitment to the promoter. Our findings are therefore consistent with studies suggesting that Set7/9 stabilizes the transcriptional preinitiation complex by methylation of TAF10 (18).

Taken together, our results suggest a model for Set7/9 action at target β-cell genes. We propose that Set7/9 is

---

FIG. 8. Loss of Set7/9 affects Pol II but not Pdx1 recruitment. βTC3 cells were transfected with siControl or siSet97 and subjected to ChIP using normal rabbit serum (–Ab) or antibody to RNA polymerase II COOH-terminal domain (+Ab). Recovery of the gene fragments was assessed by real-time PCR. Data are reported as recovery of the indicated genes following ChIP as a percent of the input levels of the genes before ChIP. A: ChIP experiment using antibody to Pdx1. B: ChIP experiment using antibody to RNA polymerase II COOH-terminal domain. Data represent the average of three independent ChIP assays from three independent siRNA transfections. *Statistically different (P < 0.05) from data of siControl transfections.
recruited to specific β-cell genes (e.g., Ins1/2 and Glut2) through interaction with factors such as Pdx1. This recruitment subsequently leads to dimethylation of H3 Lys4 within the promoter region (either directly by Set7/9 or through interaction with another methyltransferase) and recruitment of RNA polymerase II. The subsequent conversion of RNA polymerase II to its elongation isomorph requires other factors that are dependent on Pdx1. The preponderance of studies in the literature suggest that dimethylation of H3 Lys4 appears to be crucial for laying a euchromatic template at target genes, thereby leaving genes poised for transcription. Although we have demonstrated an important role for Set7/9 in the transcriptional regulation of key β-cell genes in mature cells, the role of Set7/9 in establishing transcriptional patterns during the embryonic development of β-cells remains to be determined. In future studies, we will directly address its role in embryonic development using conditional Set7/9 knockout mice.

ACKNOWLEDGMENTS

This work is supported by a grant from the Juvenile Diabetes Research Foundation (to R.G.M.) and by grants R01 DK60581 (to R.G.M.) and T32 GM007055 (to T.G.D.) from the National Institutes of Health. No potential conflicts of interest relevant to this article were reported.

We thank Dr. C. Nunemaker for use of the Ca2+ imaging equipment and Dr. K. Brayman for provision of human pancreatic sections.

REFERENCES

1. Prentki M, Nolan CJ: Islet beta cell failure in type 2 diabetes. J Clin Invest 116:1802–1812, 2006
2. Muturbaugh LC: Pancreas and beta-cell development: from the actual to the possible. Development 134:427–438, 2007
3. Babu DA, Deering TG, Mirmira RG: A feat of metabolic proportions: Pdx1 orchestrates islet development and function in the maintenance of glucose homeostasis. Mol Metab 2:43–55, 2007
4. Hay CW, Docherty K: Comparative analysis of insulin gene promoters: implications for diabetes research. Diabetes 55:3201–3213, 2006
5. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, Barrera LO, Van Calcar S, Qu C, Ching KA, Wang W, Weng Z, Green RD, Crawford GE, Ren B: Distinct and predictive histone signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 38:311–318, 2007
6. Fischle W, Wang Y, Allis CD: Histone and chromatin cross-talk. Curr Opin Cell Biol 15:172–183, 2003
7. Turner BM: Cellular memory and the histone code. Cell 111:285–291, 2002
8. Karnik SK, Hughes CM, Gu X, Roussel-Robson O, McLean GW, Xiong Y, Meyerson M, Kim SK: Menin regulates pancreatic islet growth by modulating histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A 102:14659–14664, 2005
9. Milne TA, Hughes CM, Lloyd R, Yang Z, Roussel-Robson O, Dou Y, Schnepp RW, Krankel C, Livolsi VA, Gibbs H, Hua X, Rozycki RG, Meyerson M, Hess JL: Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A 102:749–754, 2005
10. Chakrabarti SK, Francis J, Ziaesmn SM, Garney JC, Mirmira RG: Covalent histone modifications underlie the developmental regulation of insulin gene transcription in pancreatic beta cells. J Biol Chem 278:23623–23630, 2003
11. Francis J, Chakrabarti SK, Garney JC, Mirmira RG: Pdx1 links histone H3-Lys4 methylation to RNA polymerase II elongation during activation of insulin transcription. J Biol Chem 280:36242–36253, 2005
12. Wang H, Cao R, Xia L, Erdjument-Bromage H, Borchers C, Tempst P, Zhang Y: Purification and functional characterization of a histone H3 lysine 4-specific methyltransferase. Mol Cell 8:1207–1217, 2001
13. Nishioka K, Chouikov S, Sarma K, Erdjument-Bromage H, Allis CD, Tempst P, Rorbach D, Set9, a novel histone H3 lysyl methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev 16:479–489, 2002
14. Chouikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gamblin SJ, Barlev NA, Reinberg D: Regulation of p53 activity through lysine methylation. Nature 432:353–360, 2004
15. Ivanov GS, Ivanova T, Kurash J, Ivanov A, Chouikov S, Gizaftulin F, Herrera-Medina EM, Rauscher Fr, Reinberg D, Barlev NA: Methylation-activation interplay regulates p53 in response to DNA damage. Mol Cell Biol 27:6756–6760, 2007
16. Kurash JK, Lei H, Shen Q, Marston WL, Granda BW, Fan H, Wall D, Li E, Gaudet F: Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Mol Cell 29:392–400, 2008
17. Couture JF, Collazo E, Hauk G, Trievel RC: Structural basis for the methyltransferase activity site specificity of SET7/9. Nat Struct Mol Biol 13:146–146, 2006
18. Kouskouti A, Scheer E, Staub A, Tora L, Talainidn I: Gene-specific modulation of TAF10 function by SET7-mediated methylation. Mol Cell 14:175–182, 2004
19. Subramanian K, Jia D, Kapoor-Vazirani P, Powell DR, Collins RE, Sharma D, Peng J, Cheng X, Vertino PM: Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell 30:336–347, 2008
20. Chakrabarti SK, James JC, Mirmira RG: Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1: importance of chromatin structure in directing promoter binding. J Biol Chem 277:13286–13293, 2002
21. Holmeyer HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB: Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel–dependent and –independent glucose-stimulated insulin secretion. Diabetes 49:421–430, 2000
22. Yang Z, Chen M, Ellett JD, Flaklkw LB, Carter JD, Nadler JL: The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrent after islet transplantation. Transplantation 77:55–60, 2004
23. Itpe T, Francis J, Garney JC, Schisler NJ, Neshor R, Weir GC, Becker GC, Newgard CB, Griffen SC, Mirmira RG: Mechanism of insulin gene regulation by the pancreatic transcription factor Pdx-1: application of pre-mRNA analysis and chromatin immunoprecipitation to assess formation of functional transcriptional complexes. J Biol Chem 280:16708–16705, 2005
24. Jahanshahi P, Wu R, Carter JD, Nenmaker CS: Evidence of diminished glucose stimulation and endoplasmic reticulum function in non-oscillatory pancreatic islets. Endocrinology, 25 September 2008 [Epub ahead of print]
25. Ohneda K, Mirmira RG, Wang J, Johnson JD, German MS: The homeodomain of PDX-1 mediates multiple protein–protein interactions in the formation of a transcriptional activation complex on the insulin promoter. Mol Cell Biol 20:900–911, 2000
26. Ohlsson H, Karlsson K, Edlund T: IFP1, a homeodomain-containing transactivator of the insulin gene. Embo J 12:4241–4249, 1993
27. Birk JR, Schisler JC, Takeuchi K, Newgard CB, Becker TC: An adenosine vector for efficient RNA interference-mediated suppression of target genes in insulinaoma cells and pancreatic islets of Langerhans. Diabetes 53:2190–2194, 2004
28. Bisht B, Srinivasan K, Dey CS: In vivo inhibition of focal adhesion kinase causes insulin resistance. J Physiol 586:3825–3837, 2008
29. Watanabe H, Saito H, Rychahou PG, Uchida T, Evers BM: Aging is associated with decreased pancreatic acinar cell regeneration and phosphatidylinositol 3-kinase/Akt activation. Gastroenterology 120:1391–1404, 2001
30. Hengpin JC, Nenquin M, Stiemp P, Ahren B: In vivo and in vitro glucose-induced biphasic insulin secretion in the mouse: pattern and role of cytoplasmic Ca2+ amplification signals in β-cells. Diabetes 55:441–451, 2006
31. Holland AM, Gomezi L, Nassei G, Macdonald RJ, Harrison LC: Conditional deletion highlights the role of homeodomain transcription factor Pdx1 in maintenance and regeneration of β-cells in the adult pancreas. Diabetes 54:2586–2595, 2005
32. Ahlgren U, Jonsson J, Jonsson L, Simu K, Edlund H: Beta-cell-specific inactivation of the mouse Ifp/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev 12:1763–1768, 1998
33. Li Y, Reddy MA, Miao F, Shammugan N, Yee JK, Hawkins D, Ren B, Natarajan R: Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappa B dependent inflammatory genes: relevance to diabetes and inflammation. J Biol Chem 283:26771–26781, 2008
34. Kwon T, Chang HJ, Kwak E, Lee C, Joachimia K, Kim YC, Lee J, Cho Y: Mechanism of histone lysine methyl transfer revealed by the structure of SET7/9-AdoMet. Embo J 22:292–303, 2003
35. Xiao B, Jing C, Wilson JR, Walker PA, Vassiti N, Kelly G, Howell S, Taylor IA, Blackburn GM, Gamblin SJ.: Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature 421:652–656, 2003
36. Smith and Smith SC, Marzati I, Yap KL, Sampath SC, Krutchinsky AN, Mecklenbrauker I, Viale A, Rudensky E, Zhou MM, Chait BT, Taharkov A: Methylation of a histone mimic within the histone methyltransferase G9a regulates protein complex assembly. Mol Cell 27:596–608, 2007